Tessera Therapeutics
Tessera Therapeutics is a Gene & Genome Editing Platforms company founded in 2018 and based in Somerville, United States. It has raised $530M in total funding, most recently a Series C in 2022.
Founded inside Flagship Pioneering's innovation labs in 2018 by Geoffrey von Maltzahn, Jacob Rubens, Robert Citorik, and colleagues, Tessera Therapeutics is building Gene Writing — a category of genome engineering based on harnessing and re-engineering mobile genetic elements (the natural systems that move DNA and RNA around genomes) rather than CRISPR nucleases. The platform is designed to span the full range of edits: correcting single nucleotides, inserting or deleting short sequences, and writing entire genes into the genome, paired with lipid-nanoparticle delivery. The Somerville, Massachusetts company raised over $300M in a 2022 Series C with backing from Flagship, the Abu Dhabi Investment Authority, and the Alaska Permanent Fund.
Gene Writing is a non-CRISPR bet on mobile genetic elements as a more flexible way to install genes.
tesseratherapeutics.com ↗·Gene & Genome Editing Platforms·
United States·private 
